NTLA
Intellia TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The April 27 HAELO readout is a real thesis change: Intellia now has positive Phase 3 data, a rolling BLA has started, and the April financing pushes runway at least into 2028, which together meaningfully de-risk the path to a first launch.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +22.9.
What can break
Equity dilution from the April 2026 follow-on offering may cap near-term upside even after the positive HAELO readout.
Momentum
37
Value
41
Sentiment
79
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.00 · Bull $21.00 · Bear $8.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $26.12
Why
Momentum37 · Δ7d -25.7
Value41 · Δ7d -0.1
Sentiment79 · Δ7d +22.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
37
26% active weight
Current posture
7d trendImproving
Δ7d
-25.7
Δ21d
-29.0
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
79
34% active weight
Current posture
7d trendImproving
Δ7d
+22.9
Δ21d
+40.4
Why this grade
Composite grade C. Momentum 37.2 / Value 41.1 / Sentiment 78.7
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.59B
Beta
2.09
Shares Out
139.72M
P/E (TTM) · Derived
-3.0
P/S (TTM)
18.87
P/FCF (TTM) · Derived
-3.50
Rev YoY
-9.5%
EPS YoY
-26.5%
Gross Margin
+76.3%
Op Margin
-832.2%
Net Debt
-$356.56M
Current Ratio
6.10
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology